COMMUNIQUÉS West-GlobeNewswire

Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule
29/09/2026
FULLERTON, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company has regained compliance with Nasdaq’s minimum bid price rule. [...]
TETmedical Names Arjun Ishwar Chief Commercial Officer to Lead Commercial Strategy and Accelerate NSE-FAST® Toward Market Launch and Rapid Growth
29/09/2026
Veteran MedTech Commercial Builder Who Has Scaled Businesses from First Dollar to $100M+ in Revenue, Secured Coverage and Reimbursement Pathways, and Led International Expansion Joins TETmedical Ahead of Its Pivotal [...]
Standard Dental Labs Files Semiannual Report and Projects Annualized Revenue of 3.48 Times 2025 Revenue
29/09/2026
Management estimates $822,000 in annualized revenue as SDL expands digital production capabilities and appoints Dr. David Zionts as its first advisor ORLANDO, Fla., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Standard Dental [...]
Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options
29/09/2026
Simone Biles opens up about her experience managing the symptoms of these conditions and encourages long-term control of skin health Biles’ treatment, ZORYVE ® (roflumilast), is the #1 prescribed branded topical therapy [...]
SafeSpace Global Advances Addiction Treatment Vertical with Signed Statement of Work and Initial Antidote Health Ventures Deployment
29/09/2026
Agreement Moves Previously Announced Antidote Partnership into Paid Deployment KNOXVILLE, Tenn., Sept. 29, 2026 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation (OTCID: SSGC) (“SafeSpace Global” or the “Company”), a [...]
Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy
29/09/2026
Ernexa selected for the Emerging Track, recognizing the Company among emerging innovators in the cell and gene therapy sector President & CEO Sanjeev Luther to deliver an Innovation Spotlight presentation on October [...]
Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy
29/09/2026
Data support pelareorep’s potential as a backbone therapy to transform immunologically inactive liver tumors into a phenotype that will respond to immune-based intervention SAN DIEGO, Sept. 29, 2026 (GLOBE NEWSWIRE) -- [...]
NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer
29/09/2026
CARMEL, Ind., Sept. 29, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating [...]
ABBYY Appoints Paula Sanders to Chief Customer Experience Officer, Providing Customers a Single, End-to-End Experience
29/09/2026
AUSTIN, Texas, Sept. 29, 2026 (GLOBE NEWSWIRE) -- ABBYY today announced the appointment of Paula Sanders to Chief Customer Experience Officer (CCXO) to provide customers a consistent, connected experience across every [...]
Why Weight Loss Plateaus Happen: 5 Metabolic Causes
29/09/2026
Trilivy™ is designed to address the challenges of metabolic dysfunction Clients on Trilivy's Reset 5 & 1 Plan who work with a coach lose up to 10 times more weight and 17 times more fat compared to self-directed [...]
Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites
29/09/2026
NYU Langone Health is a nationally recognized academic medical center with deep expertise in spine surgery, minimally invasive procedures, robotic spine surgery, and clinical research CLARITY is a prospective, [...]
CDT Highlights Sarborg’s Expanding Quantum Computing IP Portfolio and Application to Drug Discovery
29/09/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 29, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“ CDT ” or the “ Company ”) today notes the announcement from Sarborg Limited regarding the filing of new [...]
OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences
29/09/2026
OKYO demonstrates continued commitment to optometry and ophthalmology LONDON and NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing [...]
BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis
29/09/2026
FDA Fast Track designation represents an important regulatory milestone for the Plinabulin and docetaxel combination as an anticancer regimen in 2L/3L advanced or metastatic non-squamous NSCLC without actionable genomic [...]
Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311
29/09/2026
VYD2311 met all primary and secondary endpoints comparing VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating VYD2311 safety and tolerability that is clinically and statistically superior to the safety and [...]
PolarityBio’s Phase 3 COVER DFUS II Trial Selected for First-to-Podium Presentation at SAWC Fall 2026
29/09/2026
Pivotal SkinTE® data in non-healing Wagner Grade 1 diabetic foot ulcers to be presented by Study Chair Robert S. Kirsner, MD, PhD, on October 16 SALT LAKE CITY, Sept. 29, 2026 (GLOBE NEWSWIRE) -- PolarityBio® , a late- [...]
Ocugen to Participate in Upcoming October Investor and Industry Conferences
29/09/2026
MALVERN, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that members of [...]
Boehringer Ingelheim investments into sustainability-related programs and health partnerships to reach EUR 500 million
29/09/2026
Company investments from the past five years, together with the forecast for 2026, are projected to reach EUR 500 million by year-end 2026, encompassing all expenditure on sustainability-related projects and health [...]
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
29/09/2026
LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an [...]

Pages